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Ochratoxin A (OTA) is a mycotoxin occurring naturally in
a wide range of food commodities. In animals, it has been shown
to cause a variety of adverse effects, nephrocarcinogenicity being
the most prominent. Because of its high toxic potency and the
continuous exposure of the human population, OTA has raised
public health concerns. There is significant debate on how to use
the rat carcinogenicity data to assess the potential risk to humans.
In this context, the question of the mechanism of action of
OTA appears of key importance and was studied through the
application of a toxicogenomics approach. Male Fischer rats were
fed OTA for up to 2 years. Renal tumors were discovered during
the last 6 months of the study. The total tumor incidence reached
25% at the end of the study. Gene expression profile was analyzed
in groups of animals taken in intervals from 7 days to 12 months.
Tissue-specific responses were observed in kidney versus liver. For
selected genes, microarray data were confirmed at both mRNA
and protein levels. In kidney, several genes known as markers of
kidney injury and cell regeneration were significantly modulated
by OTA. The expression of genes known to be involved in DNA
synthesis and repair, or genes induced as a result of DNA damage,
was only marginally modulated. Very little or no effect was found
amongst genes associated with apoptosis. Alterations of gene
expression indicating effects on calcium homeostasis and a dis-
ruption of pathways regulated by the transcription factors hepato-
cyte nuclear factor 4 alpha (HNF4a) and nuclear factor-erythroid
2-related factor 2 (Nrf2) were observed in the kidney but not
in the liver. Previous data have suggested that a reduction in
HNF4a may be associated with nephrocarcinogenicity. Many
Nrf2-regulated genes are involved in chemical detoxication and
antioxidant defense. The depletion of these genes is likely to
impair the defense potential of the cells, resulting in chronic
elevation of oxidative stress in the kidney. The inhibition of
defense mechanism appears as a highly plausible new mechanism,
which could contribute to OTA carcinogenicity.
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Ochratoxin A (OTA) is a naturally occurring mycotoxin
produced by several species of Aspergillus and Penicillium. As
a consequence of its widespread occurrence in a variety of food
commodities such as cereals, green coffee, cocoa, dried fruits,
and meat products (WHO, 2001), the human population is
continuously exposed to OTA, although usually only in trace
amounts.
OTA causes a range of adverse effects in monogastric
animals, with renal toxicity being the most prominent (NTP,
1989; O’Brien and Dietrich, 2005; WHO, 2001). Other OTA-
mediated toxic effects observed in vitro or in vivo include
inhibition of protein synthesis (Dirheimer and Creppy, 1991),
impairment of energetic metabolism (Gekle et al., 2005; WHO,
2001), induction of oxidative stress (Gautier et al., 2001a;
Kamp et al., 2005; Petrik et al., 2003; WHO, 2001), and
apoptosis (Gekle et al., 2005; O’Brien and Dietrich, 2005;
Petrik et al., 2003; Sauvant et al., 2005).
In a 2-year carcinogenicity study, OTA administration by
oral gavage caused dose-dependent incidence of renal tumors
in male rats, while females were much less susceptible (NTP,
1989). Similar effects were observed in mice, although at much
higher doses (Bendele et al., 1985). OTA has been suspected to
be an etiological agent in the human disease Balkan endemic
nephropathy (BEN) and in its association with an increased
incidence of urinary tract tumors (Petkova-Bocharova et al.,
1988; Plestina et al., 1990). However, causal involvement of
the toxin in these two diseases lacks robust etiological
evidence, and the actual health significance of current natural
OTA exposure in the human is still unclear.
At present, there is still insufficient mechanistic under-
standing of OTA toxicity, particularly in respect to the
occurrence of renal carcinomas. OTA has, for instance, been
shown to alter several cell-signaling pathways known to be
involved in carcinogenesis. They include modulation of the
calcium-dependent signaling and the mobilization of two
mitogen-activated protein kinases (MAPK), the extracellular
signal-regulated kinase (ERK1/2) and the c-jun amino terminal
kinase (JNK1/2) (Gekle et al., 2005; Sauvant et al., 2005).
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Since the carcinogenic mechanism remains obscure, there
is still significant debate about the best model for human
risk assessment. Knowledge of the extent of a toxicant’s
genotoxicity is vital in evaluating its potency as a carcinogen.
At present, the genotoxic status of OTA is still unclear
(Manderville, 2005; Turesky, 2005), mainly due to contradic-
tory experimental evidence. (1) Applying 32P-postlabelling,
some authors have found low levels of DNA lesions in organs
of animals treated with OTA (Castegnaro et al., 1998; Faucet
et al., 2004; Pfohl-Leszkowicz et al., 1993). These lesions have
been interpreted as OTA-specific covalent DNA adducts,
suggesting that OTA is a genotoxin sensu stricto. Such
a compound would require dose-response modeling for
quantitative risk assessment. It has, however, also been
suggested that OTA-mediated DNA lesions detected by 32P-
postlabelling may have arisen through indirect mechanisms
rather than direct DNA-binding (Gautier et al., 2001b). (2) In
studies that used radiolabeled OTA, DNA-binding could not be
detected (Gautier et al., 2001b; Gross-Steinmeyer et al., 2002;
Mally et al., 2004), indicating that the compound may not be
directly genotoxic. If this is the case, an alternative safety-
based approach would need to take into account uncertainty
factors in order to evaluate the human health risk of OTA
exposure.
The aim of the present study was to exploit the power of
toxicogenomics to seek evidence for potential involvement of
epigenetic mechanisms in OTA carcinogenesis under exposure
conditions producing a significant incidence of renal tumors
without overt toxicity. Gene expression profiles were analyzed
in kidney and liver of male Fischer (F-344) rats, given dietary
OTA over various periods ranging from 7 days to 12 months.
This duration spans the first half of the standard 2-year protocol
for studying lifetime responses to carcinogens.
MATERIALS AND METHODS
Ochratoxins. Standardized OTA production was performed by growing
A. ochraceus isolate D2306 (Harris and Mantle, 2001) in shaken solid substrate
fermentations at 28C for 2 weeks to yield a product containing 5–6 mg OTA/g.
More specifically, 40 g of sterilized shredded wheat (Cereal Partners UK,
Welwyn, UK) in 500 ml Erlenmeyer flasks was inoculated with a concentrated
spore suspension in water (16 ml), and the flasks were shaken at 200 rpm and 10
cm eccentric throw. An aliquot of each fermentation was assayed for OTA-
concentration by HPLC with diode array detection (Harris and Mantle, 2001).
Batches of fermentation product contained ochratoxin B (OTB) equivalent to
5–10% of the amount of OTA. No other mycotoxins (e.g., penicillic acid,
citrinin) were biosynthesized in this fermentation. Each week, a weighed
amount of standardized fermentation product was homogenized into powdered
standard commercial rat feed (Special Diets Services, UK) to a final
concentration appropriate for the required OTA-intake per animal. Each animal
was given 20 g of contaminated feed daily, which was always fully consumed.
Animal treatment. Male Fischer 344 (F-344) rats (B. & K. Universal Ltd.,
Hull, UK) in groups of five were administered OTA in diet given daily over
2 years. As from their initial weight of ~175 g, daily dietary intake was 300 lg
OTA/kg bw, but was held at 100 lg/rat after animals reached 333 g. Over the
period of the study, animals were housed in cages on absorbent paper under
tightly controlled conditions (21 ± 1C, 55 ± 10% relative humidity, air-
exchange, 12-h light-dark cycle). Animal growth and welfare were monitored
by regular weighing and daily surveillance. For the gene expression study, five
time points were selected to represent early (7 and 21 days) and later (4, 7, and
12 months) responses. At each time point, four control and treated animals were
randomly chosen for tissue harvest. Kidneys and liver from these rats were im-
mediately snap-frozen in liquid nitrogen. All handling and procedures were
carried out in accordance with the UK Animals (Scientific Procedures) Act 1986.
RNA isolation. Homogenates from liver and kidney tissue samples were
prepared with the FastPrep system (Q.BIOgene, Germany). Total RNA was
isolated using the Clontech Atlas Pure Total RNA Labeling System (BD
Biosciences, Switzerland) following the manufacturer’s protocol. Total RNAs
were treated with DNase I to remove genomic DNA contamination. RNA
concentration was measured with the RiboGreen RNA quantification Kit
(Molecular Probes, Eugene, OR) according to the manufacturer’s instruction.
Assessment of RNA quality and measurement of the 28S to 18S ratio were
performed by dynamic gel electrophoresis using the Agilent Bioanalyser
(Agilent Biotechnologies, Germany).
cRNA preparation. Five lg of total RNA from kidney and liver samples of
treated and control rats was used for the synthesis of double-stranded cDNA
(Superscript Choice System; Invitrogen Life Technologies, Carlsbad, CA) in
the presence of a T7-(dT) DNA oligonucleotide primer. After synthesis, cDNA
was purified by phenol/chloroform/isoamyl alcohol extraction and subsequent
ethanol precipitation. The purified cDNA was transcribed in vitro using
a MEGAscript kit (Ambion Diagnostics, Austin, TX) in the presence of
biotinylated ribonucleotides to form biotin-labeled cRNA (ENZO Life
Sciences, Farmingdale, NY). Labeled cRNA was purified using a nucleospin
matrix (Macherey-Nagel, Germany), quantified by RiboGreen, and its quality
was assessed with Agilent Bioanalyzer before subsequent fragmentation.
Hybridisation and labeling. Twenty lg of each fragmented cRNA was
hybridized to a GeneChip cartridge, rotated at 60 rpm for 16 h at 40C. Sample
was analyzed independently using the Affymetrix platform RG-U34A expres-
sion probe arrays (Affymetrix Inc., Santa Clara, CA) containing 8,799 probe
sets. For each time point, at least three independent controls and treated animals
were analyzed individually on a GeneChip cartridge. Quality control steps were
performed during the microarray procedure and were collected according to the
laboratory information management system (L.I.M.S). After hybridization,
GeneChips were washed 10 times in 63 SSPE-T at 25C, followed by four
washes in 0.53 SSPE-T at 50C. GeneChips were stained with 10 lg/ml
streptavidin-P-phycoerythrin, SAPE (Molecular Probes Inc., Eugene, OR), in
a GeneChip Fluidics Workstation 400 (Affymetrix Inc., Santa Clara, CA). The
signal was amplified using biotinylated goat antistreptavidin antibody (Vector
Laboratories, Burlingame, CA), followed from a second staining with SAPE.
The array was washed and scanned at 560 nm using a confocal laser scanner
(GeneArray Scanner 2500, Hewlett Packard).
Data analysis and clustering algorithms. Signals from scanned images
were quantified using the Affymetrix Gene Expression Analysis software
(MAS 5.0). Normalization of gene expression data was performed. Differences
in gene expression occurring in treated rats compared to controls were
calculated by applying analysis of variance (ANOVA). This analysis was
performed on log-transformed signal values for each gene individually (By-
Gene test). Three factors were used for ANOVA: treatment, time, and the
interaction between treatment and time. ANOVA between the treatments was
performed applying the Global Error Assessment method (GEA) as previously
described (Mansourian et al., 2004; Mutch et al., 2004). This approach
increases the statistical power of the data. Complete data sets generated in this
study are available at the NCBI Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/), access number GSE2852.
Gene clustering dendrograms were obtained with the software Spotfire
(Spotfire Inc.) following the UPGMA clustering and Tanimoto similarity
measure (Matter, 1997). Only genes with a significant p  0.001 in at least two
time points were included in dendrograms of differential expression of genes in
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kidney and liver. The vertical axis of each dendrogram shows individually
selected probes, whereas the horizontal axis represents the clustering level at
the time points studied (7 days, 21 days, 4 months, 7 months, and 12 months).
Single value decomposition. The variability of gene modulation induced
by OTA during the time was also investigated by a matrix factorization
technique equivalent to Principal Component Analysis (PCA), the singular
value decomposition (SVD) method (Alter et al., 2003). SVD method provides
a low-dimensional projection of the original dataset by its decomposition in
three quantities—the matrices containing the left- and right-singular vectors of
the original data matrix, and the diagonal matrix containing the singular values.
Clusters formed by the SVD method can be interpreted as the relative
frequencies with which a given gene is modulated at every one of the original
single time points which, when combined, form the temporal modes of gene
modulation. Average from each SVD-generated cluster was performed in order
to evaluate the profile of the gene expression during the time.
Real-time polymerase chain reaction (PCR). Several key genes, each of
which represents a category of genes found to be modulated by OTA, were
selected to validate the microarray data. RNA preparation, quantification, and
quality control were conducted as described above. RNA was converted to
cDNA using the two-step TaqMan Gold RT-PCR system (Applied Biosystem,
Foster City, CA) containing the TaqMan Reverse Transcription Reagents and
the TaqMan PCR Core kit for relative quantification experiments. Reverse
transcription was performed in triplicate, according to the manufacturer’s
instructions (Applied Biosystems, Foster City, CA), using the random hexamers
primer and 5 lg of pooled RNA samples. cDNA synthesis was performed in
a Thermal Cycler 9600 (Applied Biosystems) under the following conditions:
10 min at 25C, 30 min at 48C, and a final inactivation step of 5 min at 95C.
Samples were amplified in a MicroAmp 96-well reaction plate with the ABI
Prism 7000 Sequence Detection System using 1 ll of cDNA template and the
TaqMan PCR kit (Applied Biosystems). The thermocycler conditions included
two incubations of 2 min at 50C and 10 min at 95C, followed by 40 cycles,
each consisting of a denaturing step for 15 sec at 95C and a second annealing
and extension step for 1 min at 60C. Quantification of amplified PCR products
was performed using ABI Prism 7000 Sequence Detection System software
Version 1.1, normalized to the rat 18S gene as internal control. All rat PCR
probes and primers used in this study were obtained from the Assays on
Demand (AoD) Service of Applied Biosystems.
Protein expression analysis by Western blot. Correlation between mRNA
and protein expression was confirmed by Western blot. Briefly, 50 mg of liver
and kidney tissue samples were directly homogenized using RIPA (150 mM
PBS containing 1% (vol/vol) Igepal CA630, 0.5% (wt/vol) sodium deoxy-
cholate, 0.1% (wt/vol) SDS, and 5 lg/ll protease inhibitor mixture), pH 7.4
(SantaCruz Biotechnology, Santa Cruz, CA) following the manufacturer’s
instructions. Protein concentration was determined with a BioRad Protein assay
kit (Bio-Rad, Richmond, CA). Using the MiniCell XCellSureLock system
(Invitrogene), 15 lg of protein was loaded in the NuPAGE Bis-Tris Pre-Cast
Gel 4–12% System (Invitrogene Ltd, Paisley, UK). Protein was transferred to
a nitrocellulose transfer membrane (Invitrogene) for 1 h at 30 V. Transferred
membranes were probed with antibodies specific for the proteins Gstp, Gclc
(kindly offered by Dr. Leslie McLellan, Dundee University, Scotland, UK),
Oatp1 (kindly offered by Prof. B. Hagenbuch, University of Kansas Medical
Center, Kansas City, KS), HNF4a (Abcam, Cambridge, UK), Oct2 and Oat-k1
(Alpha Diagnostic, San Antonio, TX). Each blot was subsequently probed with
horseradish peroxidase linked to the specific secondary antibody. Chemilumi-
nescence of the immunoblots was detected using ECL solution (Pierce,
Rockford, IL). Membranes were wrapped in polythene film and exposed to
Kodak films.
RESULTS
OTA treatment was generally well tolerated throughout the
2-year carcinogenicity study from which the tissue samples for
the gene expression study originated. The body weight of
treated animals did not differ significantly from that of control
animals. All tumors that were found before the 2-year end point
of the carcinogenicity study were from animals that had been
euthanized because of loss of condition. The first renal tumor
was found 75 weeks after OTA treatment commenced (Fig. 1).
The total incidence of animals with a renal tumor reached 25%
(n ¼ 64) at the end of the study. At least 75% of these animals
had unilateral renal carcinoma as determined by tumor size,
proliferating and disorganized histopathology, and abundance
of metastasis (Mantle et al., in press).
Gene Selection and Clustering
Applying the stringency criteria for selection of significantly
differentiated genes, statistical analysis revealed that the
expression of 470 genes in the kidney and 233 genes in the
liver were differentially modulated (p  0.001 in at least two
time points) by the OTA treatment. Of these, only 45 genes
were modulated in both kidney and liver.
Hierarchical clustering analysis was performed for kidney
and liver mRNA expression profiles (Figs. 2A and 2B). The
vertical axis of the dendrograms represents each transcript, and
the x-axis represents the various time points, and at the
intersection of these two values, the expression intensity as
compared to control (fold-expression) can be seen. The
organization in both the horizontal and vertical axes represents
the similarity of the expression values as detailed by the tree
connecting each category. The distance of the connecting lines
in the tree represents the extent of similarity. Gene expression
clusters were generated accordingly; interestingly, the 7-day
and 12-month profiles exhibited the most similar time points
(in terms of the expression values of the affymetrix probes at
these time points) in both organs. In the kidney, these two time
points taken together are then most similar to the 7-month time
point; these three are most similar to the 21-day and, finally, the
4-month time point. In the liver, these two time points taken as
a cluster are most similar to the 12-month, 7-day, and finally,
the 7-month time point. In both organs, down regulation was
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FIG. 1. Cumulative renal tumor incidence during the last quarter of live in
rats given OTA-contaminated diet continuously for up to 2 years.
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the predominant effect, with 60% and 56% of genes down-
regulated in kidney and liver, respectively.
Further analysis of the gene expression profile in kidney
and liver was performed by application of a single value
decomposition (SVD) method along the time coordinate. The
mean fold-expression values were plotted as a function of
time (Figs. 2C and 2D). In both organs, eight clusters with
differentiated time-dependent expression profile were identi-
fied. The modulation of OTA-induced gene expression was
generally less than two-fold. The two main clusters include
only genes that, over the five time points, are either continu-
ously up-regulated (31% in kidney, 25% in liver) or
FIG. 2. Hierarchical clustering representing the genes significantly modulated ( p  0.001) in at least two time points in the kidney (A) and the liver (B). The
y-axis of the dendrograms represents the genes and the corresponding expression level displayed in green for down-regulation, red for up-regulation, and black for
insignificant change in gene expression. Time points of analysis are plotted on the x-axis at 7 days (7D), 21 days (21D), 4 months (4M), and 12 months (12M), and
their corresponding time clustering is shown at the top of each dendrogram. Mean values of the fold-expression change for the eight clusters, as determined by the
single value decomposition (SVD) method, are plotted as a function of time points for kidney (C) and liver (D). The two main clusters identified in each organ are
highlighted in bold (red squares: up-regulation; grey triangles: down-regulation). They illustrate the gene expression pattern typical for the majority of significantly
modulated genes.
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continuously down-regulated (47% in kidney, 27% in liver). No
other clear and easily interpretable time-dependent trends, such
as an early and/or late response, could be observed.
Grouping of genes modulated by OTA was performed
according to their biological functions. For this analysis, a gene
ontology approach was applied to genes exhibiting at least 1.5-
fold expression values. The number of genes attributed to each
functional class is depicted in Figure 3, showing a wide
diversity of highly tissue-selective biological responses. In the
kidney, genes involved in xenobiotic metabolism and oxida-
tive stress response were generally down-regulated by OTA,
whereas this group of genes was much less modulated in the
liver. Interestingly, many of these genes share the antioxidant
regulatory element (ARE) as a regulatory motif (Table 1).
Other gene classes, such as several enzymes involved in fatty
acid metabolism and cytochrome P450, were also selectively
down-regulated in the kidney of OTA-treated animals. Many of
these genes possess a common promoter targeted by the
transcription factor hepatocyte nuclear factor alpha (HNF4a).
Several genes, which belong to different functional classes and
were down-regulated following OTA-treatment, were identified
as being under transcriptional control of HNF4a (Table 2). Of
interest was the finding that the mRNA specific for HNF4a
itself was down-regulated.
Expression of many transporter genes was down-regulated in
the kidney (Table 3). Several genes known as markers of kidney
injury, cell regeneration, and oncogenesis were significantly
modulated by OTA. For example, the kidney injury molecule
(KIM-1, 4.4-fold) and the survival markers c-myc (3.7-fold),
Akt-1 (1.7-fold), Polo-like kinase (Plk, 1.5-fold), and Cdkn1a
alias p21 (2.3-fold) were up-regulated. The regucalcin (REG),
also known as the senescence marker protein 30 (Smp30), was
down-regulated more than 10-fold by OTA.
Only small changes occurred in expression of genes known
to be involved in DNA synthesis and repair or in genes induced
as a result of DNA damage. Few genes associated with DNA
repair were slightly down-regulated. Similarly, very little or no
effects were found on expression of apoptosis-related genes.
Three genes involved in the regulation of protein synthesis
were modulated by OTA. The prostaglandin F2 receptor nega-
tive regulator (Ptgfrn) and the eukaryotic translation initia-
tion factor 4E binding protein 1 (Eif4ebp1) were up-regulated
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FIG. 3. Biological function clustering. Genes exhibiting at least 1.5-fold up- or down-regulation in kidney (white columns) and liver (black columns), plotted
as a function of the total number of genes in each category.
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(3.2- and 1.5-fold, respectively), while the Elongation factor
1-alpha 1 (eEF1A-1) was down-regulated (3.3-fold).
Confirmation of Microarray Expression Data
In order to confirm the microarray data, selected gene
products assigned to various functional classes were analyzed
by quantitative real-time PCR (TaqMan-PCR). As with the
microarray data, TaqMan RT-PCR data is presented as fold-
expression value of OTA-treated samples as compared to
controls. As shown in Figure 4, expression values obtained
with RT-PCR are highly comparable to the data generated by
microarray technology.
Protein expression of six genes was measured from samples
taken at the early and late time-points (21 days and 12 months)
by Western blot analysis. A good correlation was observed be-
tween microarray data and measured protein expression (Fig. 5).
DISCUSSION
OTA is a common trace contaminant of some foodstuffs. It
produces various toxicological effects, the most relevant being
nephrotoxicity and nephrocarcinogenicity in rat (NTP, 1989).
There is significant debate on the use of rat carcinogenicity data
to assess the potential carcinogenic risk to humans. A very
relevant question with respect to OTA-mediated carcinogenic-
ity and risk assessment is whether the toxin acts through
genotoxic or epigenetic mechanisms. For human safety
assessment, a nongenotoxic mechanism of OTA would trigger
the use of a health-based guidance value established by the
application of uncertainty factors to the pivotal No Observed
Adverse Effect Level obtained in animal studies (WHO, 2001).
The present work was aimed to generate data relevant to
understanding the mechanism of OTA action and should help to
select the most appropriate risk assessment procedure. This
study was intended better to reflect the pattern of human
exposure, and therefore, for the first time, oral feeding was
chosen as the route of administration. This allowed ingestion of
OTA in the most natural way for the experimental animals,
homogenized into feed and consumed as desired, mainly in the
dark part of the diurnal cycle. The dose was chosen to produce
tumors, although avoiding overt nephrotoxicity, which could
interfere with the carcinogenic process. A previous acute study
had shown a marked difference between the toxicity of single
TABLE 1
Genes Modulated by OTA under Transcriptional Control of Nrf2
Accession no. Gene title Symbol Folda Fold 7D Fold 21D Fold 4M Fold 7M Fold 12M
Xenobiotic metabolism
X65296 carboxylesterase 3 Ces3 3.4* 1.5 9.8* 4.2* 3.3* 2.0*
M33747 UDP-glucuronosyltransferase 2 family, member 5 Ugt2b5 2.7* 2.5 1.3 5.2* 3.1 3.0
X81395 carboxylesterase 1 Ces1 1.9* 2.0 2.2 2.7 1.8 1.3
S81433 Heme-oxygenase 2/5# region HMOX2 1.6* 2.4 3.0* 1.1 1.0 1.6
AF045464 aflatoxin B1 aldehyde reductase Akr7a3/ Afar 1.5* 1.0 2.0* 2.1* 1.2 1.4
J02722cds heme oxygenase 1 Hmox1 2.1* 1.4 4.4 1.6* 1.3 3.2*
Carbon metabolism
AI008020 malic enzyme 1 Me1 1.8* 1.3 2.8* 3.2* 1.0 1.7
AJ005046 fructose bisphosphatase 2 Fbp2 2.6* 1.8 1.8 2.9 4.1 3.2
Glutathionerelated genes
J05181 glutamate-cysteine ligase catalytic subunit Gclc 4.8* 3.4* 8.0* 6.0* 2.7* 5.8*
S65555 glutamate cysteine ligase, modifier subunit Gclm 3.1* 3.5* 3.4* 4.1* 1.7 3.5*
L38615 glutathione synthetase Gss 1.9* 1.1 2.5* 2.7* 1.8* 1.8
AI138143 glutathione S-transferase, theta 2 Gstt2 1.8* 1.7 1.8* 2.6* 1.7* 1.6
X03518 gamma-glutamyl transpeptidase Ggtp 1.8* 1.0 1.8 2.6* 1.8 2.1*
X02904 glutathione S-transferase, pi 2 Gstp2 1.7* 1.4 1.5 2.0* 1.8 2.1*
S72506 glutathione-S-transferase, alpha type2 Gsta2 3.8* 1.6 2.9 21.3* 4.4 4.3
U76252 gamma-glutamyltransferase-like activity 1 Ggtla1 1.7* 2.8* 2.2 1.5 1.1 1.2
Amino acid metabolism
M93297 ornithine aminotransferase Oat 2.7* 1.6 6.2* 2.4* 2.8* 2.1*
Others
X06107 insulin-like growth factor 1 Igf1 1.9* 2.8 1.5 3.8 2.9 4.9*
L48060 prolactin receptor Prlr 1.7* 1.1 3.4* 1.6 1.4 1.8
X71127 complement component 1, q subcomponent,
beta polypeptide
C1qb 2.0* 1.6 3.6* 1.7 2.0* 1.8
aAverage fold-change in gene expression from the five time points (7D and 21D days and 4M, 7M, and 12M months).
*Statistical significance represented by the alpha risk <0.001.
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daily doses by gavage and the same amount homogenized into
feed (Miljkovic et al., 2003). In the initial phase of the study
(until rats reached 333 g), the chosen dose used (300 lg/kg bw)
was twice that estimated as the highest average daily intake in
the NTP study (NTP, 1989), in which the toxin was adminis-
tered by oral gavage. After rats reached 333 g, the dose was
held to 100 lg/rat, aimed to gradually reduce the two-fold
difference in intake between the NTP and the present regime as
the body weight further increased. This protocol was consid-
ered to better mimic the human intake pattern (Mantle et al.,
in press). Dosing adult rats according to body weight (as in the
NTP study) would have resulted in an increasing exposure to
OTA (due to weight gain from fat accumulation), which would
not have reflected exposure of human adults. At a given
occurrence level of OTA, human intake is likely to be relatively
stable because of the limited expected age-dependent varia-
tions in body weight and food intake. The various selected time
points represented early (7 and 21 days) and late (up to 12
months) exposure stages. The treatment was well tolerated, and
cumulative incidence of animals with a renal tumor of 25% had
occurred by the 2-year end point of the experiment. This
incidence of carcinomas was significantly lower than that
observed in the NTP study at the highest dose (Mantle et al.,
in press). However, the development of renal cancer in this
study makes it a suitable source for studying carcinogenic
processes. The difference of cancer incidence between the two
studies highlights the importance of the route of administration
for tumor outcomes.
OTA-modulated gene expression profiles were obtained in
both kidney, the toxin’s main target organ, and liver. Overall,
the effects observed were relatively modest. Real-time PCR
data confirmed the results. The effect on abundance of certain
mRNAs correlated with the change in expression of respective
proteins, suggesting that such OTA-induced changes could be
of biological significance. The various clustering approaches
showed the distinctive difference between kidney and liver
responses, consistent with the known organ selectivity of OTA
carcinogenicity in the male rat. It is also possible that the
apparently higher susceptibility of kidney is due to a dose-
response effect from the elevated content and the prolonged
residence of OTA in that organ. Indeed, it is well documented
TABLE 2
Genes Modulated by OTA under Transcriptional Control of HNF4a
Accession no. Gene title Gene symbol Folda Fold 7D Fold 21D Fold 4M Fold 7M Fold 12M
Glucose metabolism
X05684 pyruvate kinase, liver and RBC Pklr 1.6* 1.8 2.1* 1.8 1.6 1.1
Androgen and estrogen metabolism
L19998 sulfotransferase family 1A,
phenol-preferring, member 1
Sult1a1 1.9* 1.3 2.0* 2.2* 2.0* 1.9*
Lipids and steroid metabolism
M73714 aldehyde dehydrogenase family 3,
subfamily A2
Aldh3a2 1.9* 1.6 1.2 4.4* 1.0 4.6*
D90109 fatty acid Coenzyme A ligase Facl2 1.6* 2.2* 1.1 1.7 1.5 1.8*
Xenobiotic metabolism
J02657 cytochrome P450, subfamily IIC Cyp2c 10.0* 8.2* 7.5* 64.9* 1.8 13.5*
J02861 cytochrome P450 2c13 Cyp2c13 2.4* 2.5* 1.1 2.6* 4.8* 2.2*
M18335 cytochrome P450, 2c39 Cyp2c39 1.5* 1.3 1.2 1.1 3.0* 2.0*
Lipids and retinal transport
M10934 retinol binding protein RBP4 2.2* 1.3 4.9* 4.6* 1.7* 1.8*
S69874 fatty acid binding protein 5,
epidermal
Fabp5 2.1* 1.6 2.7* 1.8* 2.1* 2.5*
M27440 apolipoprotein B Apob 1.6* 1.4 1.8* 2.7 1.7* 1.1*
D38380 transferrin Tf 2.5* 3.2* 1.9* 1.4 3.0* 3.9*
Transcription factors
X57133 hepatocyte nuclear factor 4, alpha Hnf4a 2.4* 1.9 4.3* 1.3 3.8* 2.0*
Coagulation cascades and blood
pressure
M12112 angiotensinogen Agt 3.5* 1.1 10.5* 5.8* 2.2* 4.4*
M81397 coagulation factor 2 F2 1.5* 1.6* 2.3* 1.7* 1.1 1.1
Transporters (See Table 3)
aAverage fold-change in gene expression from the five time points (7D and 21D days and 4M, 7M, and 12M months).
*Statistical significance represented by the alpha risk <0.001.
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TABLE 3
Transporter-Related Genes Modulated by OTA
Accession no. Gene title Gene symbol Folda Fold 7D Fold 21D Fold 4M Fold 7M Fold 12M
Renal proximal
tubule Function Regulation Ref.
U15176 ATPase, Naþ/Kþ Atp1a4 4.3* 3.3 4.3 6.4* 4.6 3.6 basolateral Intracellular sodium
and potassium balance
PKC, ERK1/2 Khundmiri et al.,
2005
AB004559 solute carrier
family 22,
member 6
Slc22a6/rOAT1 2.7* 2.7* 4.4* 3.6* 1.8 1.9 basolateral Endogenous and
exogenous anions
Ochratoxin A
PKC, ERK1/2 Koepsell and Endou,
2004
Tsuda et al., 1999
D79981 solute carrier
family 21,
member 4
Slc21a4/OAT-K1 2.5* 2.7 5.6* 3.0 1.2 1.8 apical Organic anions,
xenobiotics,
Ochratoxin A
Takeuchi et al., 2001
L19031 solute carrier
family 21,
member 1
Slc21a1/Oatp1 2.5* 1.6 3.8* 2.9 3.9* 1.3 apical Organic anions
Ochratoxin A
PKC,
testosterone
Terlouw et al., 2003
Hagenbuch and
Meier, 2003
AB005547 aquaporin 8 Aqp8 2.5* 4.6* 1.0 2.1 2.1 4.4* apical/
basolateral
H2O, Urine
concentration
Vasopressin,
adenylate
cyclase
Verkman et al., 1996
D13871 solute carrier
family 2,
member 5
Slc2a5/GLUT5 2.2* 1.5 2.6* 2.7* 2.4* 2.2* apical fructose transport Swissprot
D86086 ATP-binding
cassette
Abcc2, Mrp-2 2.1* 2.1 1.9 2.5* 1.9 2.2 apical Organic anions,
glutathione conjugated
Lee and Kim, 2004
AB013455 solute carrier
family 34,
member 1
Slc34a1, NaPi-2 1.8* 1.5 3.0* 1.9 1.6* 1.3* apical Na/Pi cotransport Dietary Pi
intake and
parathyroid
hormone
Magagnin et al., 1993
D83044 solute carrier
family 22,
member 2
Slc22a2/Oct2 1.7* 1.0 3.0* 2.0 1.8* 1.4* basolateral Endogenous and
exogenous cations
>Male Koepsell and Endou,
2004
Lee and Kim, 2004
M80804 solute carrier
family 3,
member 1
Slc3a1/NBAT 1.7* 1.5 2.4* 2.0* 1.6 1.2 apical Amino acid transport Wells and Hediger,
1992
X67948 aquaporin Aqp1 1.7* 1.8 2.5* 1.5 1.5 1.4 apical/
basolateral
H2O, Urine
concentration
Vasopressin,
adenylate cyclase
Ma et al., 1998
U76379 solute carrier
family 22,
member 1
Slc22a1/OCT1A 1.5* 1.9* 1.3 1.7* 1.5 1.1 basolateral Organic cations,
anions, weak bases
PKC/PKA,
TK cGMP
Koepsell and Endou,
2004
Lee and Kim, 2004
U28504 solute carrier
family 17,
member 1
Slc17a1/ NaPi-1 1.5* 1.3 2.3* 1.8 2.3* 1.5 apical Na/Pi co-transport Swissprot
M81855 P-glycoprotein/
multidrug
resistance 1
Mdr1/Pgy1 4.6* 1.0* 6.9 21.8* 6.5* 2.2 apical Removal of
xenobiotics
Lee and Kim, 2004
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that OTA is actively transported in kidney cells (Gekle et al.,
2005; O’Brien and Dietrich, 2005; WHO, 2001).
Hierarchical clustering analysis resulted in the identification
of relatively complex and unexpected time-related responses.
For example, a cluster was noted between the early response (at
7 days) and the late response (at 12 months). Currently, this
finding is difficult to interpret. Time-related differences may
occur as a result of toxicokinetics, treatment duration, and/or
age-specific factors. The experimental design and the statistical
approach applied in the present study did not allow thorough
addressing of these factors.
General Markers of Nephrotoxicity and Carcinogenicity
Up-regulation of the prototypical renal toxicity marker
kidney injury molecule (KIM-1) was observed in treated
animals. KIM-1 is a type-1 membrane protein highly expressed
both in early stage renal tubular injury and in regenerating
proximal tubule epithelial cells (Ichimura et al., 1998). Early
induction of KIM-1 expression with a maximum at 21 days (21-
fold) shows that the OTA-dose in the present study produced
some nephrotoxicity, even if not clinically apparent. From
a mechanistic perspective, this finding may be relevant. It is
acknowledged that toxicity might induce tissue regeneration
and cell proliferation, which may then promote tumor de-
velopment. OTA-induced proliferation has been observed
in vivo (NTP, 1989) and in vitro (Hong et al., 2000; Kamp
et al., 2005). However, there was no histological evidence of
renal cell proliferation at any time point analyzed in this study,
apart from the consistent presence of karyomegalic nuclei (data
not shown). In the present study, genes implicated in cell
survival and proliferation were induced by OTA, including c-
myc (Amati et al., 1998), Akt1 (Vanhaesebroeck and Alessi,
2000), and Plk (Holtrich et al., 1994). In addition, a strong up-
regulation of P-glycoprotein (P-gp) was observed. P-gp
belongs to the ATP-binding cassette (ABC) multidrug trans-
porter superfamily overexpressed in tumor cells (Thomas and
Coley, 2003).
Inhibition of protein synthesis is thought to be a major mode
of OTA toxicity, although the exact molecular mechanism
involved is not known (Creppy et al., 1983). However, only few
differentially expressed genes relate directly to a known
mechanism of protein synthesis inhibition. The prostaglandin
F2 receptor negative regulator (Ptgfrn; Orlicky, 1996) and the
eukaryotic translation initiation factor 4E binding protein 1
(Eif4ebp1; Gingras et al., 1999) were up-regulated. Both are
documented to be involved in negative regulation of protein
synthesis. In contrast, elongation factor 1-alpha 1 (eEF1A-1)
was down-regulated. This protein is known to promote the
GTP-dependent binding of aminoacyl-tRNA to the A-site of
ribosomes during protein biosynthesis (Petroulakis and Wang,
2002). Although our data imply inhibition of protein synthesis,
comprehensive data on protein expression and modification
would be required for a more definite conclusion. For example,
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FIG. 4. Quantitation of gene expression changes for selected kidney genes as measured by TaqMan and Affymetrix methods at three time points: 21 days
(black), 4 months (white), and 12 months (grey). The relative quantities of TaqMan RT-PCR products were normalized to the 18S rat housekeeping gene. TaqMan
RT-PCR data are presented as the fold expression values as compared to those of control samples from technical replicates from pooled kidney mRNA (n ¼ 3).
(A–B) Nephrotoxicity markers. (C–D) HNF4a-regulated genes. (E–F) Transport-related genes. (G–H) Nrf2-regulated genes.
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it is known that the activity of the Eif4ebp1 protein is
dependent on its phosphorylation status (Gingras et al., 1999).
One of the most striking effects obtained in the present study
was a strong down-regulation of regucalcin, also known as the
senescence marker protein30 (Smp30). The maximum effect
was observed after 21 days of treatment. In kidney tubule cells,
regucalcin is known to play a role in the regulation of intra-
cellular Ca2þ homeostasis. The reduction of regucalcin is
compatible with documented effects of OTA on intracellular
calcium and on calcium signaling homeostasis (Sauvant et al.,
2005). In rat renal cortex, regucalcin was shown to produce
a suppressive effect on DNA synthesis (Xue et al., 2000;
Morooka and Yamaguchi, 2002). Interestingly, recent studies
have suggested that regucalcin may possess tumor suppression
activity in hepatoma cells (Tsurusaki and Yamaguchi, 2003,
2004). Inhibition of regucalcin expression was also observed
with other nephrotoxicant and nephrocarcinogenic compounds
like cisplatin (Huang et al., 2001; Misawa and Yamaguchi,
2001). Taken together, these data confirm a potential key role
of calcium homeostasis in the mechanism of OTA action,
which deserves further investigation.
OTA was found to significantly reduce the expression of
a number of genes encoding transport proteins, such as those
involved in organic anion transport. Similar trends were
observed in an acute and high-dose experiment (Luhe et al.,
2003). Importantly, these results support previous physiolog-
ical data in vitro and in vivo showing that chronic treatment
with OTA resulted in an impairment of the secretion of organic
anions in the proximal tubules (Gekle and Silbernagl, 1994;
Gekle et al., 2005; Sauvant et al., 2005). In this context it is
interesting to note that angiotensinogen mRNA expression was
down-regulated in our study. This may explain the effects of
OTA on renal hemodynamics, which is thought to be mediated
by angiotensin II (Gekle et al., 2005).
The transport proteins Oat1, Oat-k1, and Oatp1 are well
documented to selectively transport OTA (Gekle and Silbernagl,
1994; Gekle et al., 2005; O’Brien and Dietrich, 2005; Zepnik
et al., 2003). In our study they were markedly down-regulated
at RNA and protein levels, indicating that OTA is likely to affect
its own toxicokinetics. In addition, the down-regulation of
transporters involved in the excretion of xenobiotic metabolites
(e.g., multidrug resistance-associated protein 2, mrp2) may
possibly result in interactions between OTA and other toxic
chemicals.
Recently, it has been proposed that gene expression profiling
can identify distinctive fingerprints or signatures to discrimi-
nate between compounds that act either as directly genotoxic or
are genotoxic through indirect mechanisms (Dickinson et al.,
2004; Hu et al., 2004). Although this method of classification
still requires validation, a trend has been observed in which
direct-acting genotoxins induce toxicity-associated pathways
followed by early modulation of specific genes related to DNA-
damage. Interestingly, the genes reported as potentially specific
for direct-acting genotoxins were not modulated in our study,
which may strongly suggest an indirect genotoxic mechanism
for OTA.
Disruption of Biological Pathways
Analysis of DNA-binding sites revealed that many genes
down-regulated by OTA share the motif 5#-AGGTCA-3# as
a DNA-binding domain. This sequence is the regulatory motif
through which the transcription factor HNF4a acts (Ellrott
et al., 2002). This strongly suggests that OTA may disrupt
HNF4a-dependent regulatory pathways. The exact mechanism
involved in the inhibition of HNF4a-regulated gene expression
is not clear, although it was found that down-regulation of
HNF4a expression was observed at both mRNA and protein
levels.
From the perspective of cancer development, the biological
significance of down-regulation of HNF4a-regulated genes is
difficult to define. Many of the HNF4a target genes play im-
portant roles in development, differentiation, and homeostasis
FIG. 5. Correlation between changes in gene and protein expression.
Kidney protein lysates from control and OTA-treated animals were analyzed by
Western blots and visualized by chemiluminescence. Transferred membranes
were probed with antibodies specific to the following proteins: Gstp, Gclc,
HNF4a, Oct2, Oat-k1, Oatp1 (cortex only), and Oatp1 (medulla only). Three
controls and three samples from OTA-treated animals were analyzed at 21 days
and 12 months.
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(Sladek, 1993), and the depletion of HNF4a-pathway was
previously associated with cancer development (Sel et al.,
1996). HNF4a-expression and activity was analyzed in human
renal carcinomas (Sel et al., 1996). The data indicated that in
tumor samples both the expression and activity of HNF4a were
reduced as compared to normal tissue, suggesting that this
pathway might be an important molecular mechanism in renal
carcinogenesis. However, the present analyses occurred well
before any renal tumors were evident in the OTA-treated rats.
In the kidney, OTA treatment resulted in an average 10-fold
down-regulation of the expression of the male-specific, HNF4a-
regulated cytochrome P450 CYP 2C11. CYP 2C11 is involved
in phase I metabolism of endogenous compounds (i.e., steroids)
and several xenobiotics (Riddick et al., 2004). A potential role of
CYP 2C11 in bioactivation of OTA was suggested (Pfohl-
Leszkowicz et al., 1998), but data indicating a strong down-
regulation of this gene do not support this hypothesis.
OTA has been reported to induce oxidative stress. For
example, an increased formation of malondialdehyde (MDA)
was observed in the kidney of rats exposed to 120 lg/kg bw/day
of OTA for 60 days (Petrik et al., 2003). Other studies
confirmed lipid peroxidation as a result of OTA exposure
(Omar et al., 1990; Sauvant et al., 2005). Contrary to this, in
another study, treatment of male rats with OTA (up to 2.0 mg/kg
bw administered by oral gavage) did not increase the formation
of biomarkers of oxidative damage such as the lipid perox-
idation marker MDA in plasma, kidney, and liver, or the DNA
damage marker 8-oxo-7,8-dihydro-2#deoxyguanosine in kid-
ney DNA (Gautier et al., 2001b). However, a significant
increase in the expression of the marker of oxidative stress
response HSP32 protein was observed in kidney but not in liver.
Surprisingly, in the present study, many genes normally induced
by oxidative stress were down-regulated during OTA treatment.
This response was only observed in kidney, and the mechanism
of this down-regulation is still unknown. Interestingly, these
genes share the antioxidant regulatory element (ARE) as
a regulatory motif in their promoter region. The ARE-motif is
recognized by the nuclear factor-erythroid 2-related factor 2
(Nrf2), a member of the ‘‘Cap-n-Collar’’ family of basic-region
leucine zipper transcription factors (Mathers et al., 2004). Nrf2
is involved in both the basal expression and the induction of
genes encoding mainly for detoxication, cytoprotective, and
antioxidant enzymes (Lee and Johnson, 2004; Nguyen et al.,
2004). These proteins are responsible for cellular redox status
and for cellular defense against oxidative damage. We are
currently studying inhibition of Nrf2-activation by OTA as
a molecular mechanism involved in OTA toxicity.
Although the expression of most of the renal Nrf2-regulated
genes seemed to be inhibited by OTA treatment, a limited
number of them appeared to be induced (e.g., Gsta2). It is
important to note that, for many genes, the 5# promoter region
may contain multiple binding sites specific for several tran-
scription factors, and therefore the observed effects on mRNA
expression may be the combined effects on different transcrip-
tion factors. Previous investigations have provided evidence
that phase II enzymes may not be regulated exclusively by
Nrf2-mediated mechanisms (Kang et al., 2003). For example,
recent studies indicated that Nrf2 might not significantly
contribute to the expression of Gsta1/2 in the mouse small
intestine (McMahon et al., 2001). Our results show that some
Nrf2-regulated genes are not down- but up-regulated, suggest-
ing that OTA may also alter other signaling pathways that have
not yet been identified.
The toxicological consequences of the OTA-mediated down-
regulation of many Nrf2-regulated genes are likely to be
biologically significant. It is well documented that chemicals
inducing an oxidative stress response through activation of
Nrf2 are associated with chemoprotective properties (Chen and
Kong, 2004; Zhang and Gordon, 2004). With OTA, the
inhibition of expression of genes involved in the biosynthesis
of glutathione (including the rate-limiting Gclc) is likely to
result in a reduction of the cellular glutathione content, as
already documented in OTA-treated cell cultures (Schaaf et al.,
2002). Because of its major importance in the cellular redox-
balance, a reduction of intracellular glutathione content should
compromise the cellular defense against oxidative damage. 4-
Hydoxynonenal (4-HNE) is a reactive metabolite resulting
from lipid peroxidation that forms DNA adducts (Hartley et al.,
1995). Because of the affinity to conjugate 4-HNE with
glutathione, Gstp is thought to play a role in the detoxication
of this lipid peroxidation product (Hartley et al., 1995). It can
be hypothesized that the OTA-mediated down-regulation of
Gstp may impair the detoxication of 4-HNE and thus result in
increased oxidative damage.
Many Nrf2-regulated gene products down-regulated by OTA
are involved in xenobiotic detoxication processes. They in-
clude several glutathione S-transferases and UDP-glucuronyl-
transferases. Their reduced expression may possibly result in
a higher concentration of xenobiotics, normally detoxified by
these enzymes, which could act synergistically with OTA, as
suggested for OTA and other mycotoxins (Creppy et al., 2004).
Finally, an attempt to link HNF4a and Nrf2-pathways
pointed to protein kinase C (PKC) as a common regulatory
feature. PKC is the major kinase involved in ARE-mediated
gene induction by Nrf2 (Bloom and Jaiswal, 2003; Numazawa
et al., 2003) and in activation of the HNF4apathway
(Hashimoto et al., 2005; Roy et al., 2001). Notably, in our
study several transport-related genes, reported to be regulated
through PKC-dependent processes, were also down-regulated
by OTA (see Table 2). These data strongly suggest that
disruption of PKC-mediated processes may play a role in the
toxicity of OTA (Fig. 6). Further investigation is necessary to
confirm this hypothesis.
Summary and Conclusion
In the present study significantly different gene expression
profiles were observed in kidney and liver of male Fischer rats
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following chronic dietary exposure to OTA in a concentration
sufficient to cause renal carcinoma late in life. Gene expression
data indicated occurrence of renal toxicity, which may involve
oxidative damage and eventually lead to cell proliferation and
cancer. Gene expression analysis pointed toward predominant
involvement of epigenetic mechanisms in OTA carcinogenic-
ity. These mechanisms may include alteration of calcium
homeostasis and disruption of pathways regulated by the
transcription factors HNF4a and Nrf2. The depletion of
Nrf2-regulated enzymes is likely to impair the cellular defense
potential, resulting in chronic elevation of oxidative stress in
the kidney. Sources of oxidants can be either endogenous
(normal physiological processes) or exogenous (xenobiotics).
Low concentration of antioxidants can result in cell pro-
liferation and, ultimately, cancer development (Klaunig and
Kamendulis, 2004). Therefore, inhibition of cellular defense
appears to be a highly plausible novel mechanism, which could
contribute to OTA-mediated carcinogenicity. However, it has to
be acknowledged that the present data do not provide any
absolute demonstration of a direct link between the gene
expression effects observed and the late development of
tumors. Further investigations are necessary to further establish
the relevance of the biological effects to the carcinogenic
process. In addition, it has to be noted that the interpretation of
gene expression data in this study has focused on significantly
modulated genes. It is, of course, feasible that subtle changes in
the expression of other genes, together with cell signaling and
post-translational modification processes, which were not
further analyzed in this study, are also implicated in OTA
carcinogenesis and could help to accomplish the comprehen-
sion of the OTA mechanism of action.
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